Alzamend Neuro ALZN Stock
Alzamend Neuro Price Chart
Alzamend Neuro ALZN Financial and Trading Overview
| Alzamend Neuro stock price | 2.06 USD |
| Previous Close | 3.42 USD |
| Open | 3.4 USD |
| Bid | 3.24 USD x 100 |
| Ask | 3.31 USD x 100 |
| Day's Range | 3.25 - 3.49 USD |
| 52 Week Range | 2.75 - 135.54 USD |
| Volume | 203.34K USD |
| Avg. Volume | 1.68M USD |
| Market Cap | 2.63M USD |
| Beta (5Y Monthly) | -0.277 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.19 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 180 USD |
ALZN Valuation Measures
| Enterprise Value | -1224942 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.7208791 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.6123973 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.295 |
Trading Information
Alzamend Neuro Stock Price History
| Beta (5Y Monthly) | -0.277 |
| 52-Week Change | -89.64% |
| S&P500 52-Week Change | 13.16% |
| 52 Week High | 135.54 USD |
| 52 Week Low | 2.75 USD |
| 50-Day Moving Average | 3.51 USD |
| 200-Day Moving Average | 8.68 USD |
ALZN Share Statistics
| Avg. Volume (3 month) | 1.68M USD |
| Avg. Daily Volume (10-Days) | 260.76K USD |
| Shares Outstanding | 800.95K |
| Float | 715.92K |
| Short Ratio | 0.03 |
| % Held by Insiders | 3.22% |
| % Held by Institutions | 0.87% |
| Shares Short | 136.1K |
| Short % of Float | 17.48% |
| Short % of Shares Outstanding | 16.98% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:9 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | April 30, 2024 |
| Most Recent Quarter (mrq) | January 31, 2025 |
| Next Fiscal Year End | April 30, 2025 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -106.084% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -4157212 USD |
| Net Income Avi to Common (ttm) | -4226937 USD |
| Diluted EPS (ttm) | -1210.59 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 3.36M USD |
| Total Cash Per Share (mrq) | 4.58 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 5.438 |
| Book Value Per Share (mrq) | 5.356 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -7306188 USD |
| Levered Free Cash Flow (ttm) | -5735064 USD |
Profile of Alzamend Neuro
| Country | United States |
| State | GA |
| City | Atlanta |
| Address | 3480 Peachtree Road NE |
| ZIP | 30326 |
| Phone | 844 722 6333 |
| Website | https://www.alzamend.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 4 |
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Q&A For Alzamend Neuro Stock
What is a current ALZN stock price?
Alzamend Neuro ALZN stock price today per share is 2.06 USD.
How to purchase Alzamend Neuro stock?
You can buy ALZN shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Alzamend Neuro?
The stock symbol or ticker of Alzamend Neuro is ALZN.
Which industry does the Alzamend Neuro company belong to?
The Alzamend Neuro industry is Biotechnology.
How many shares does Alzamend Neuro have in circulation?
The max supply of Alzamend Neuro shares is 3.8M.
What is Alzamend Neuro Price to Earnings Ratio (PE Ratio)?
Alzamend Neuro PE Ratio is now.
What was Alzamend Neuro earnings per share over the trailing 12 months (TTM)?
Alzamend Neuro EPS is -1.19 USD over the trailing 12 months.
Which sector does the Alzamend Neuro company belong to?
The Alzamend Neuro sector is Healthcare.
Alzamend Neuro ALZN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23454.09 USD — |
+0.17
|
7.06B USD — | 23271.83 USD — | 23499.93 USD — | — - | 7.06B USD — |
| US Tech Health Care IXHC | 1200.15 USD — |
+1.71
|
— — | 1182.78 USD — | 1200.82 USD — | — - | — — |
- {{ link.label }} {{link}}